Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18107133 | 1.00 | — | — | |
| SCHEMBL6323393 | 1.00 | ALDH1A1 (0.41) | ALDH1A1HSD17B10HSD11B1HSD11B2POLB | |
| SCHEMBL1047397 | 0.96 | — | — | |
| SCHEMBL1047645 | 0.87 | — | — | |
| SCHEMBL3986300 | 0.87 | — | — | |
| SCHEMBL122550 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL15467307 | 0.85 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL831131 | 0.80 | ALDH1A1 (0.32) | ALDH1A1HSD17B10 | |
| SCHEMBL6900404 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 | |
| SCHEMBL4752145 | 0.77 | ALDH1A1 (0.37) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1480639-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | Warner-Lambert Company LLC (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | TAYLOR CHARLES PRICE (US) | 2003-10-23 | — | — | US | disclosed |
| WO-2003070237-A1 | COMBINATIONS OF AN ALPHA-2-DELTA LIGAND WITH A SELECTIVE INHIBITOR OF CYCLOOXYGENASE-2 | WARNER-LAMBERT COMPANY LLC (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199567-A1 | Combinations of an alpha-2-delta ligand with a selective inhibitor of cyclooxygenase-2 | CACNG2, GABRB2, CACNG4 | ALDH1A1 543/4885HSD17B10 1094/4885HSD11B1 962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.